Article
Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
Gastroenterology - 1 Nov 2017
Bloemendaal Felicia M, Levin Alon D, Wildenberg Manon E, Koelink Pim J, McRae Bradford L, Salfeld Jochen, Lum Jenifer, van der Neut Kolfschoten Marijn, Claassens Jill W, Visser Remco, Bentlage Arthur, D'Haens Geert R A M, Verbeek J Sjef, Vidarsson Gestur, van den Brink Gijs R
Abstract excerpt
BACKGROUND & AIMS: Although tumor necrosis factor (TNF) antagonists reduce many clinical features of inflammatory bowel disease, complete mucosal healing occurs in fewer than 50% of patients. The Fc-region of monoclonal antibodies against TNF has immunosuppressive properties via effects on macrophage polarization. We examined the interaction between the anti-TNF Fc-region and Fcγ receptors (FcγR), and whether the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.